Low dose rofecoxib, inflammation and prostacyclin synthesis in acute coronary syndromes

Kuklińska AM, Musiał WJ, Kamiński KA, Kralisz P, Modrzejewski W, Sobkowicz B, Dobrzycki S, Stec S, Wojtkowska I

Abstract

Purpose: To assess the influence of low dose rofecoxib on inflammatory mediators and prostacyclin synthesis in patients with acute coronary syndromes (ACS) in a short- term follow up. 
Material and methods: Twenty nine patients with ACS without ST elevation were randomized to simvastatin alone or together with low dose rofecoxib. Serum levels of interleukin 6 (IL-6), 6-keto-PGF-1 – stable product of prostacyclin (PGI2) and hs-C-reactive protein (hs-CRP) were assessed on enrollment and after 30-day follow up. 
Results: Combination of rofecoxib with statin significantly decreased levels of hs-CRP after one month therapy (5.21 mg/l ± 4.12 vs 2.11 mg/l ± 2.1; p=0.0092). This effect was not evident in a group on statin alone (3.95 mg/l ± 3.33 vs 2.48 mg/l ± 2.39; p=0.31). 6-keto-PGF-1 increased not significantly in both groups. IL-6 concentration has not changed during follow up.
Conclusions: Low dose of selective COX-2 inhibitor exerts significant anti-inflammatory effect and does not diminish PGI2 synthesis in study group of patients with ACS.

Key words: 	acute coronary syndromes (ACS), inflammation, simvastatin, cyclooxygenase-2 inhibitors, prostacyclin.